Kardigan (KARD) stock
Follow KARD's trial news. Members get an alert when Kardigan files news, and see its trials, share raises, and its CEO's filings.
What's next for KARD, and how long its cash lasts
From Kardigan’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
$598M in cash
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why it's down
Down 39% in 3 months, 26% under its 50-day average.
Down more than its industry: the 88 other stocks in it fell a median 3% over the same 3 months.
−2Dilution 103.5% more shares outstanding than a year ago
1 more thing pulling KARD's score down, for members
What's next
Expected to report Mon Nov 9, before the open
After its last report it closed +4.7%.
Tue Dec 15: IPO lockup endsAt the open. The 180-day lockup ends.
1 more date ahead for members: the IPO anniversary
What would turn KARD's score around: 3 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
KARD has 2 of 14 checks firing
One per group is shown here.
How KARD ranks in Pharma
KARD is #73 of 89 by Quality Score. The top three are shown with their scores, and the rest by name.
GMAB11/1419
ABBV7/1418
LLY7/1417
JNJOpen for its score
PFEOpen for its score
KARD2/14-2
When does KARD report, and what happens after?
Expected to report Mon Nov 9, before the open (in 40 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 11, 2026Before open | Before open | +1.4% | +4.7% | -2.5% |
Who is trading KARD
Insiders
3 insiders bought $90M across 3 filings in the last 6 months. No open-market sales on record. The newest:
About Kardigan
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of KARD's score, with the points and the reason
- All 14 checks on KARD and on all 2,953 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on KARD
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
Nothing for the first 8 days. After that, one plan with everything in it, only if you choose to subscribe: $29 a month, $69 for three months, or $249 a year. Payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.